Oral Drug Wins FDA Approval for Chronic Hives

(Medage today) – The FDA approved the oral remibrubrutinib (Rhapsido) as a second -line treatment of chronic spontaneous hives (CSU), or chronic hives, Navartis announced on Tuesday. Indicated for adults with stubborn symptoms despite the use of …